Preclinical studies in breast and colorectal carcinoma models demonstrated tumor uptake of 89Zr-nimotuzumab increasing up to 168 h post-injection, and, notably, EGFR expression was clearly visualized as early as 24 h post-injection [15]. Here, EGFR is linked to neoplasm.